-The Telegraph New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India. The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines,...

-The Telegraph New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine. Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against...

-Down to Earth US actions jeopardise India's pro-poor patent laws that promote generic drugs production, says online global petition More than 75,000 people have requested Prime Minister Narendra Modi not to succumb to US pressure on Intellectual Property Rights (IP). With trade and intellectual property rights featuring prominently in the agenda of US president Barak Obama's India visit, civil society groups have expressed concern that talks on these issues are designed to make...

-Vikalp Once again, India is under pressure from the US to revise its patent law. Anyone familiar with the activities of the United States Trade Representatives (USTR) would know that this is nothing new. It has been among the USTR's primary mandates to use trade restrictions in order to persuade (to put it mildly) countries to strengthen their IPR laws. There is, however, a qualitative difference between the actions it has...

-The Hindu In a significant development for the pharmaceutical industry, the Supreme Court has rejected multinational Bayer's appeal to block production and sales of the low cost version of its kidney cancer drug, sorafenib tosylate (branded as Nexavar), by Natco Pharmaceuticals. Hyderabad-based Natco was granted the first and to date only compulsory licence (CL) by the government in 2012 to make and sell a patented drug at a fraction of the...